Puberty blockers are banned in the UK

None

NEGATIVE
ToplinePuberty blockers will no longer be prescribed to minors under age 18 in England outside of regulated clinical trials, the country’s National Health Service announced Tuesday, following an earlier review by the agency, the latest development in the controversial treatment that has sparked protests in the U.S., as well, over gender-affirming care in children.
An earlier review by England’s National Health Service found a “lack of consensus and open dialogue” … [+] about gender dysphoria.
Getty ImagesKey FactsPuberty blockers—used to delay the effects of puberty—will no longer be available to anyone under age 18 being treated by the state-funded NHS, a decision junior health minister Maria Caulfield said would “ensure care is based on evidence, expert clinical opinion” that is “in the best interests of the child.” The NHS called for an independent review of gender identity treatments for minors in 2020 amid a “significant increase” in referrals to the Gender Identity Development Service, which is scheduled to close at the end of March.
The agency released an interim report from its review in February 2022, which indicated a “lack of consensus and open dialogue” about gender dysphoria while questioning how medical professionals should respond.
There are fewer than 100 children on puberty blockers who will continue their treatment at Leeds and University College London Hospital.
What To Watch ForFormer Prime Minister Liz Truss called for the British government to support a bill proposed last week that would prevent the private sale of puberty blockers.
The NHS said it hopes to have a study about the long-term effects of puberty blockers by December.
Big Number5,986.
That’s how many minors were referred to the Gender Identity Development Service from 2020 to 2022, compared to just over 500 between 2011 and 2013.
Surprising FactBillionaire Elon Musk reacted to the agency’s decision by referring to puberty blockers as “sterilization drugs,” suggesting they were banned “due to potentially severe negative effects.”Key BackgroundThe NHS is one of several European health agencies to open a review into gender-affirming services over a lack of evidence supporting hormonal treatment for minors.
Dr. Hilary Cass, who authored the agency’s review, expressed concern over what she said was insufficient evidence supporting gender-affirming services as the number of minors requesting access rapidly increased.
Only one facility in the U.K. provided access to gender-affirming services at the time, which Cass noted was “not sustainable.” Cass also questioned whether children were supported by medical professionals if they decided against transitioning.
TangentOther countries have debated access to gender-affirming care for minors in recent years.
Shortly after the NHS review, Sweden’s healthcare agency updated its healthcare guidelines preventing minors from accessing gender-affirming care, suggesting evidence for “hormonal interventions” for minors is “of low quality” and that treatments may present risks.
Several states in the U.S. have sought to ban or restrict access to certain types of gender-affirming care for minors, despite opposition by organizations including the American Medical Association and American Academy of Pediatrics.
Former President Donald Trump said last year he would assign federal agencies to “stop” healthcare providers from giving gender-affirming care if reelected, suggesting the treatments were “child abuse” and “child sexual mutilation.”Further ReadingHormone Therapy Lessened Depression, Lowered Suicide Risk Among Transgender Adults, Study Says (Forbes)

Summary.

After an earlier review by the agency, the National Health Service of England announced on Tuesday that puberty blockers will no longer be prescribed to minors under the age of 18 outside of regulated clinical trials. This is the latest development in the contentious treatment that has sparked protests in the U.S. S. also regarding child care that is gender affirming.

A “lack of consensus and open dialogue” was noted in a previous review conducted by the National Health Service of England. Regarding gender dysphoria [+]. Getty Photo.

Important Details.

In order to “ensure care is based on evidence, expert clinical opinion” that is “in the best interests of the child,” junior health minister Maria Caulfield announced that anyone under the age of 18 receiving treatment from the state-funded NHS would no longer be able to receive puberty blockers, which are used to delay the effects of puberty. In response to a “significant increase” in referrals to the Gender Identity Development Service, which is set to close at the end of March, the NHS demanded an independent review of gender identity treatments for minors in 2020. A “lack of consensus and open dialogue” regarding gender dysphoria was noted in an interim report the agency released in February 2022, raising concerns about the appropriate course of action for medical professionals. Less than a hundred kids on puberty blockers will stay on at Leeds and University College London Hospital to receive their treatment.

Things to Be Aware Of.

A bill that was put forth last week that would forbid the private sale of puberty blockers was demanded of the British government by former prime minister Liz Truss. According to the NHS, a study on the long-term impacts of puberty blockers should be available by December.

Large Sum.

5 986. This is the number of minors who were referred to the Gender Identity Development Service between 2020 and 2022, as opposed to the slightly over 500 who did so between 2011 and 2013.

Surprising Fact.

The agency’s decision was met with criticism from billionaire Elon Musk, who called puberty blockers “sterilization drugs” and claimed they were outlawed “due to potentially severe negative effects.”. “.

Essential Background.

Because there is insufficient data to support hormonal treatment for minors, the NHS is one of several European health organizations that has launched an investigation into gender-affirming services. As the number of minors seeking access to gender-affirming services increased quickly, Dr. Hilary Cass, the author of the agency’s review, voiced concern about what she claimed was insufficient evidence to support these services. Just one establishment in the U.S. KK. at the time, which Cass observed was “not sustainable,” allowed access to gender-affirming services. Cass further questioned whether medical professionals supported kids who chose not to transition.

Digression.

Access to care that is gender affirming for minors has been a topic of discussion in other nations recently. Sweden’s healthcare organization revised its guidelines shortly after the NHS review, barring minors from receiving gender-affirming care and implying that the evidence for “hormonal interventions” for minors is “of low quality” and that treatments may be dangerous. Numerous states within the United States. s. despite opposition from groups like the American Medical Association and American Academy of Pediatrics, attempted to outlaw or restrict access to specific forms of gender-affirming care for minors. When he declared last year that, if reelected, he would order federal agencies to “stop” healthcare providers from providing gender-affirming care, implying that the procedures amounted to “child abuse” and “child sexual mutilation.”. “.

Additional Reading.

According to a study, hormone therapy decreased transgender adults’ risk of suicide and lessened depression (Forbes).

Leave a Reply

scroll to top